3 research outputs found
Farmakoterapija gojaznosti: danas i sutra
Obesity is a chronic, progressive, and recurring disease. The prevalence of obesity has
reached pandemic proportions, along with overweight-related conditions like diabetes,
cardiovascular diseases, and certain cancers. Reducing residual morbidity is the main goal of
obesity treatment. Pharmacotherapy is intended for patients who have not responded to lifestyle
interventions. There are currently six anti-obesity medications (orlistat, phentermine/topiramate,
naltrexone/bupropion, liraglutide, semaglutide, and tirzepatide) approved for long-term obesity
management. Most of them, except orlistat, predominantly act centrally by increasing satiety, as
well as reducing appetite and food reward. The most effective anti-obesity drugs are semaglutide
and tirzepatide, which might provide weight loss of more than 10% of the initial weight. Although
all anti-obesity medications have been demonstrated to improve cardiometabolic risk factors, only
liraglutide and semaglutide lower the risk of major cardiovascular events in patients with or
without established cardiovascular disease. A personalized approach, considering both drug
(weight-reducing capacity and drug safety) and patient (comorbidities, age, and the patientβs
preferences) features, guarantees the best results. In this article, we will critically appraise the
efficacy and safety of currently approved anti-obesity medications and those in the pipeline.Gojaznost je hroniΔna, progresivna i recidivirajuΔa bolest. Prevalencija gojaznosti dostiΕΎe pandemijske razmere, baΕ‘ kao i komorbiditeti povezani sa gojaznoΕ‘Δu poput dijabetesa, kardiovaskularnih bolesti i izvesnih karcinoma. Glavni cilj leΔenja gojaznosti je smanjenje rezidualnog morbiditeta. Farmakoterapija je namenjena pacijentima koji nisu odgovarajuΔe reagovali na izmenu ΕΎivotnog stila. Trenutno je Ε‘est lekova odobreno za dugoroΔno leΔenje gojaznosti (orlistat, fentermin/topiramat, naltrekson/bupropion, liraglutid, semaglutid i tirzepatid). VeΔina njih, osim orlistata, preteΕΎno deluje centralno poveΔanjem oseΔaja sitosti, kao i smanjenjem apetita i hranom izazvanog "nagraΔivanja". NajveΔu efikasnost u redukciji poviΕ‘ene telesne mase (preko 10%) ostvaruju semaglutid i tirzepatid. Iako su svi lekovi za leΔenje gojaznosti pokazali povoljan uticaj na kardiometaboliΔke faktore rizika, samo je za liraglutid i semaglutid pokazano da smanjuju rizik od velikih kardiovaskularnih dogaΔaja kod pacijenata sa ili bez potvrΔene kardiovaskularne bolesti. Personalizovani pristup, koji uzima u obzir karakteristike leka (efikasnost u smanjenju telesne mase i bezbednost leka) i karakteristike pacijenta (komorbiditeti, starost i preferencije), garantuje najbolje rezultate. U ovom radu Δemo se kritiΔki osvrnuti na efikasnost i bezbednost trenutno odobrenih lekova za leΔenje gojaznosti i onih koji su u finalnoj fazi kliniΔkog ispitivanja
Development of logistics models, from population to modern pharmacodynamic models
Π£Π²ΠΎΠ΄: ΠΡΠΈΠΊΠ°Π· ΡΠ΅ΠΎΡΠΈΡΠ΅ ΠΎ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΠΈΡΠ°Π»Π½ΠΈΠΌ ΡΠ΅Π΄Π½Π°ΡΠΈΠ½Π°ΠΌΠ° ΠΈ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΠΈΡΠ°Π»Π½ΠΈΠΌ ΡΠ΅Π΄Π½Π°ΡΠΈΠ½Π°ΠΌΠ° ΡΠ° ΡΠ°Π·Π΄Π²ΠΎΡΠ΅Π½ΠΈΠΌ ΠΏΡΠΎΠΌΠ΅Π½ΡΠΈΠ²ΠΈΠΌΠ°, ΠΊΠ°ΠΎ ΠΈ Π½Π°ΡΡΠ°Π½ΠΊΠΎΠΌ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π° ΠΈ ΡΠΈΡ
ΠΎΠ²ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½ΠΎΠΌ.
Π¦ΠΈΡ ΡΠ°Π΄Π°: ΠΡΠΎΡΡΠ°Π²Π°ΡΠ΅ ΡΠ°Π·Π²ΠΎΡΠ° ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠΊΠΈΡ
Π»ΠΎΠ³ΠΈΡΡΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π° Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ Π΄ΠΎΡΡΡΠΏΠ½Π΅ ΡΠ΅Π»Π΅Π²Π°Π½ΡΠ½Π΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΈ ΠΏΡΠΎΠ½Π°Π»Π°Π·Π°ΠΊ Π²Π΅Π·Π΅ ΠΌΠΎΠ΄Π΅Π»Π° (ΠΈΠ½ΡΠ΅ΡΠ΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°ΡΠ½ΠΎΡΡ) ΡΠ° Π΄ΡΡΠ³ΠΈΠΌ Π½Π°ΡΡΠ½ΠΈΠΌ ΠΏΠΎΡΠΈΠΌΠ°, ΠΊΠ°ΠΎ ΡΡΠΎ ΡΠ΅ ΡΠ°ΡΠΌΠ°ΡΠΈΡΠ°.
ΠΠ°ΡΠ΅ΡΠΈΡΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π΅: Π£ΠΏΠΎΠ·Π½Π°Π²Π°ΡΠ΅ ΡΠ° ΠΠ°Π»ΡΡΡΠΎΠ²ΠΈΠΌ ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΠΎΠ½ΠΈΠΌ ΠΌΠΎΠ΄Π΅Π»ΠΎΠΌ, ΡΠ΅Π³ΠΎΠ²ΠΎΠΌ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡΠΎΠΌ - ΠΠ΅Π»Ρ
ΡΡΡΡΠΎΠ²ΠΈΠΌ ΠΈ ΠΠ΅Π»ΡΠΎΠ²ΠΈΠΌ ΠΌΠΎΠ΄Π΅Π»ΠΎΠΌ, Π»ΠΈΠ½Π΅Π°ΡΠ½ΠΎΠΌ ΠΈ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠΊΠΎΠΌ ΡΠ΅Π³ΡΠ΅ΡΠΈΡΠΎΠΌ, ΠΊΠ°ΠΎ ΠΈ Π»ΠΎΠ³ΠΈΡ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡΠΎΠΌ, ΡΠ²Π΅ Ρ ΡΠ²ΡΡ
Ρ ΠΊΠ°ΠΊΠΎ Π±ΠΈ ΡΠ΅ ΡΠ°Π·ΡΠΌΠ΅ΠΎ Π½Π°ΡΡΠ°Π½Π°ΠΊ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π°, ΠΊΠΎΡΠΈ ΡΠ΅ ΠΎΠΏΠΈΡΡΡΡ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠΊΠΈΠΌ Π·Π°ΠΊΠΎΠ½ΠΈΡΠΎΡΡΠΈΠΌΠ°.
Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ: ΠΠ½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΈ ΠΈΠ·ΡΡΠ°Π²Π°ΡΠ΅ΠΌ ΡΠ΅Π»Π΅Π²Π°Π½ΡΠ½Π΅ Π΄ΠΎΡΡΡΠΏΠ½Π΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΡΠΎΡΠ΅Π½Π° ΡΠ΅ Π²Π΅Π·Π° ΠΈΠ·ΠΌΠ΅ΡΡ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΠΊΠ΅ ΠΈ ΡΠ°ΡΠΌΠ°ΡΠΈΡΠ΅, ΠΊΠ°ΠΎ ΠΈ ΠΏΠΎΡΠ°ΡΡΠ΅ΡΠ΅ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π° - Log-Π»ΠΈΠ½Π΅Π°ΡΠ½ΠΎΠ³, Π»ΠΈΠ½Π΅Π°ΡΠ½ΠΎΠ³, Emax ΠΈ ΡΠΈΠ³ΠΌΠΎΠΈΠ΄Π½ΠΎΠ³ Emax ΠΌΠΎΠ΄Π΅Π»Π°, ΡΠΈΡ
ΠΎΠ²Π° ΠΏΡΠΈΠΌΠ΅Π½Π° ΠΈ Π·Π½Π°ΡΠ°Ρ.
ΠΠ°ΠΊΡΡΡΠ°ΠΊ: ΠΠ±ΡΠ°ΡΠ΅Π½ ΡΠ΅ ΡΠ°Π·Π²ΠΎΡ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π°, ΠΎΠ΄ ΠΏΡΠ²ΠΈΡ
Π»ΠΎΠ³ΠΈΡΡΠΈΡΠΊΠΈΡ
Π΄ΠΎ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π°. ΠΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠΊΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½ΠΈΡΡ ΡΡΠ°ΡΠΈΡΠ½Π΅ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΡΠ΅, Π²Π΅Ρ ΡΠ΅ ΡΠ° Π½Π°ΠΏΡΠ΅ΡΠΊΠΎΠΌ Π½Π°ΡΠΊΠ΅ ΠΈ Π½Π°ΡΡΠ½ΠΈΡ
ΡΠ°Π·Π½Π°ΡΠ° ΠΌΠ΅ΡΠ°ΡΡ, ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΡΡΡ ΠΈ Π½Π°ΡΡΠ°ΡΡ Π½ΠΎΠ²ΠΈ. Π£Π½Π°ΠΏΡΠ΅ΡΠ΅ΡΠ΅ΠΌ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π°, ΡΠΈΡ
ΠΎΠ²ΠΈΠΌ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠ°ΡΠ΅ΠΌ ΠΌΠΎΠ³Ρ Π½Π°ΡΡΠ°ΡΠΈ Π½Π΅ΠΊΠΈ Π½ΠΎΠ²ΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΊΠΎΡΠΈ ΠΌΠΎΠ³Ρ ΠΏΠΎΡΠ»ΡΠΆΠΈΡΠΈ Π·Π° ΠΎΠΏΠΈΡΠΈΠ²Π°ΡΠ΅ Π±ΡΠΎΡΠ½ΠΈΡ
ΠΏΠΎΡΠ°Π²Π° Ρ ΡΠ²Π΅ΡΡ ΠΊΠΎΡΠ΅ ΡΡ ΠΏΡΠ΅Π΄ΠΌΠ΅Ρ ΠΈΠ·ΡΡΠ°Π²Π°ΡΠ°.Introduction: Presentation of theories on differential equations and, differential equations with separated changes, as well as the emergence of logistic models and their application.
The Aim: Studying the development of mathematical logistics models by analyzing the available relevant literature and finding the connection of the model (interdisciplinarity) with other scientific fields, such as pharmacy.
Material and Methods: Introduction to Malthus population model, its modification - Velhruts and Celtic model, linear and logistic regression, as well as logit transformation, all for the purpose of understanding the origin of pharmacodynamic models, which are described by mathematical laws.
Results: By analyzing and studying the relevant available literature, the connection between mathematics and pharmacy was noticed, as well as the explanation of pharmacodynamic models - Log-linear, linear, Emax and sigmoid Emax models, their application and significance.
Conclusion: The development of mathematical models, from the first logistical to pharmacodynamic models, is discussed. Mathematical models are not static categories, but change, modify and create new ones with the progress of science and scientific knowledge. With the improvement of logistics models, their modeling can create some new models that can be used to describe numerous phenomena in the world that are the subject of study
Effects of vortioxetine in animal model of migraine
Π£Π²ΠΎΠ΄: ΠΠΈΠ³ΡΠ΅Π½Π° ΡΠ΅ ΠΏΡΠ΅ΠΏΠΎΠ·Π½Π°ΡΠ° ΠΊΠ°ΠΎ ΡΠ΅Π΄Π°Π½ ΠΎΠ΄ Π²ΠΎΠ΄Π΅ΡΠΈΡ
Π·Π΄ΡΠ°Π²ΡΡΠ²Π΅Π½ΠΈΡ
ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π½Π° Π³Π»ΠΎΠ±Π°Π»Π½ΠΎΠΌ Π½ΠΈΠ²ΠΎΡ, ΡΠ΅Ρ ΡΠ΅ ΠΏΡΠ°ΡΠ΅Π½Π° ΠΎΠ½Π΅ΡΠΏΠΎΡΠΎΠ±ΡΠ΅Π½ΠΎΡΡΡ ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΌ ΠΊΠ²Π°Π»ΠΈΡΠ΅ΡΠΎΠΌ ΠΆΠΈΠ²ΠΎΡΠ° ΠΎΠ±ΠΎΠ»Π΅Π»ΠΈΡ
. ΠΡΠ΅ΠΊΠΎ 50% ΠΏΠ°ΡΠΈΡΠ΅Π½Π°ΡΠ° ΡΠ° ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠΌ Π½ΠΈΡΠ΅ Π·Π°Π΄ΠΎΠ²ΠΎΡΠ½ΠΎ ΡΠ²ΠΎΡΠΈΠΌ Π»Π΅ΡΠ΅ΡΠ΅ΠΌ. ΠΠΎΡΡΠΎΡΠ΅ Π΄ΠΎΠΊΠ°Π·ΠΈ ΠΎ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡΠΈ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ²Π°, ΠΏΠΎΡΠ΅Π±Π½ΠΎ ΠΎΠ½ΠΈΡ
ΡΠ° ΠΌΡΠ»ΡΠΈΠΌΠΎΠ΄Π°Π»Π½ΠΈΠΌ Π΄Π΅ΡΡΡΠ²ΠΎΠΌ (Π°ΠΌΠΈΡΡΠΈΠΏΡΠΈΠ»ΠΈΠ½), ΠΈ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠ΅ Π·Π° ΡΠΈΡ
ΠΎΠ²Ρ ΠΏΡΠΈΠΌΠ΅Π½Ρ Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈ ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠ·Π½Π΅ Π³Π»Π°Π²ΠΎΠ±ΠΎΡΠ΅. ΠΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½ ΡΠ΅ Π½ΠΎΠ²ΠΈ ΠΌΡΠ»ΡΠΈΠΌΠΎΠ΄Π°Π»Π½ΠΈ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ² ΡΠ° Π½Π΅Π΄Π°Π²Π½ΠΎ ΠΏΠΎΡΡΡΠ»ΠΈΡΠ°Π½ΠΈΠΌ Π°Π½Π°Π»Π³Π΅ΡΡΠΊΠΈΠΌ ΡΠ²ΠΎΡΡΡΠ²ΠΈΠΌΠ°.
Π¦ΠΈΡ ΡΠ°Π΄Π°: 1) ΠΡΠΏΠΈΡΠ°ΡΠΈ Π°Π½Π°Π»Π³Π΅ΡΡΠΊΡ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ Π²ΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½Π° Ρ ΠΏΠΎΡΠ΅ΡΠ΅ΡΡ ΡΠ° ΡΡΠΌΠ°ΡΡΠΈΠΏΡΠ°Π½ΠΎΠΌ Π½Π°ΠΊΠΎΠ½ ΠΏΠ΅ΡΠΎΡΠ°Π»Π½Π΅ Π°ΠΊΡΡΠ½Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅ Ρ ΠΌΠΎΠ΄Π΅Π»Ρ Π°ΠΊΡΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠ·Π½Π΅ Π³Π»Π°Π²ΠΎΠ±ΠΎΡΠ΅; 2) ΠΡΠΏΠΈΡΠ°ΡΠΈ Π°Π½Π°Π»Π³Π΅ΡΡΠΊΡ Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ Π²ΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½Π° Ρ ΠΏΠΎΡΠ΅ΡΠ΅ΡΡ ΡΠ° ΠΏΡΠΎΠΏΡΠ°Π½ΠΎΠ»ΠΎΠ»ΠΎΠΌ Π½Π°ΠΊΠΎΠ½ ΠΏΠΎΠ½ΠΎΠ²ΡΠ΅Π½Π΅ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠΊΠ΅ ΠΏΠ΅ΡΠΎΡΠ°Π»Π½Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅ Ρ ΠΌΠΎΠ΄Π΅Π»Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½Π΅.
ΠΠ°ΡΠ΅ΡΠΈΡΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π΅: ΠΠΎΠ΄Π΅Π» Π°ΠΊΡΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠ·Π½Π΅ Π³Π»Π°Π²ΠΎΠ±ΠΎΡΠ΅ ΠΏΠΎΡΡΠ°Π²ΡΠ΅Π½ ΡΠ΅ Π°ΠΊΡΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½ΠΎΠΌ Π½ΠΈΡΡΠΎΠ³Π»ΠΈΡΠ΅ΡΠΈΠ½Π° (10 mg/kg, ΠΈΠ½ΡΡΠ°ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»Π½ΠΎ), Π΄ΠΎΠΊ ΡΠ΅ ΠΌΠΎΠ΄Π΅Π» Ρ
ΡΠΎΠ½ΠΈΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½Π΅ ΠΏΠΎΡΡΠ°Π²ΡΠ΅Π½ ΠΏΠΎΠ½ΠΎΠ²ΡΠ΅Π½ΠΎΠΌ, ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΠ΅Π½ΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½ΠΎΠΌ Π½ΠΈΡΡΠΎΠ³Π»ΠΈΡΠ΅ΡΠΈΠ½Π°, ΡΠ²Π°ΠΊΠΎΠ³ Π΄ΡΡΠ³ΠΎΠ³ Π΄Π°Π½Π° Ρ Π΄Π΅Π²Π΅ΡΠΎΠ΄Π½Π΅Π²Π½ΠΈΠΌ ΡΠΈΠΊΠ»ΡΡΠΈΠΌΠ° ΠΊΠΎΠ΄ ΠΌΡΠΆΡΠ°ΠΊΠ° ΠΌΠΈΡΠ΅Π²Π° C57BL/6 ΡΠΎΡΠ°. ΠΠΎΠ½ΠΎΠ²ΡΠ΅Π½Π° ΠΏΡΠΈΠΌΠ΅Π½Π° Π½ΠΈΡΡΠΎΠ³Π»ΠΈΡΠ΅ΡΠΈΠ½Π° Π΄ΠΎΠ²ΠΎΠ΄ΠΈ Π΄ΠΎ ΡΠ°Π·Π²ΠΎΡΠ° Ρ
ΡΠΎΠ½ΠΈΡΠ½Π΅ Π±Π°Π·Π°Π»Π½Π΅ ΠΈ Π°ΠΊΡΡΠ½Π΅ Π±ΠΎΠ»Π½Π΅ ΠΏΡΠ΅ΠΎΡΠ΅ΡΡΠΈΠ²ΠΎΡΡΠΈ. ΠΠ° ΠΏΡΠΎΡΠ΅Π½Ρ ΡΠ°Π·Π²ΠΎΡΠ° Π±ΠΎΠ»Π½Π΅ ΠΏΡΠ΅ΠΎΡΠ΅ΡΡΠΈΠ²ΠΎΡΡΠΈ, ΠΊΠ°ΠΎ ΠΈ Π°Π½ΡΠΈΠ½ΠΎΡΠΈΡΠ΅ΠΏΡΠΈΠ²Π½ΠΎΠ³ Π΄Π΅ΡΡΡΠ²Π° ΠΈΡΠΏΠΈΡΠΈΠ²Π°Π½ΠΈΡ
ΡΡΠ΅ΡΠΌΠ°Π½Π°, ΠΊΠΎΡΠΈΡΡΠ΅Π½ΠΈ ΡΡ ΡΠ΅ΡΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΡΠΈΡΠ°Π½ΠΎΠ³ Π±ΠΎΠ»Π½ΠΎΠ³ ΠΏΠΎΠ½Π°ΡΠ°ΡΠ° (von Frey ΡΠ΅ΡΡ β ΠΌΠ΅Ρ
Π°Π½ΠΈΡΠΊΠΈ ΡΡΠΈΠΌΡΠ»ΡΡ ΠΈ ΠΎΡΠΎΡΠ°ΡΠΈΡΠ°Π»Π½ΠΈ Π³Π»ΡΡΠ°ΠΌΠ°ΡΠ½ΠΈ ΡΠ΅ΡΡ β Ρ
Π΅ΠΌΠΈΡΡΠΊΠΈ ΡΡΠΈΠΌΡΠ»ΡΡ), ΠΊΠ°ΠΎ ΠΈ ΡΠ΅ΡΡ Π½Π΅ΠΏΡΠΎΠ²ΠΎΡΠΈΡΠ°Π½ΠΎΠ³ Π±ΠΎΠ»Π½ΠΎΠ³ ΠΏΠΎΠ½Π°ΡΠ°ΡΠ° (ΡΠ΅ΡΡ ΠΊΠΎΠΏΠ°ΡΠ°), ΠΊΠΎΡΠΈ ΡΠ΅ ΡΡΠ΅Π΄Π½ΠΎ ΠΎΠ΄ΡΠ°Π· ΠΎΠΏΡΡΠ΅ Π΄ΠΎΠ±ΡΠΎΠ±ΠΈΡΠΈ ΠΆΠΈΠ²ΠΎΡΠΈΡΠ°. ΠΠΎΠ±ΠΈΡΠ΅Π½ΠΈ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ°Π½ΠΈ ΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΠΎΠΌ ΡΠ΅Π΄Π½ΠΎΡΠ°ΠΊΡΠΎΡΡΠΊΠ΅/Π΄Π²ΠΎΡΠ°ΠΊΡΠΎΡΡΠΊΠ΅ ANOVA-Π΅ (ΡΠ· Tukey post hoc Π°Π½Π°Π»ΠΈΠ·Ρ).
Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ: Π£ ΠΌΠΎΠ΄Π΅Π»Ρ Π°ΠΊΡΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠ·Π½Π΅ Π³Π»Π°Π²ΠΎΠ±ΠΎΡΠ΅ Π·Π°Π±Π΅Π»Π΅ΠΆΠ΅Π½ ΡΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠΊΠΈ Π·Π½Π°ΡΠ°ΡΠ°Π½, ΡΠΏΠΎΡΠ΅Π΄ΠΈΠ² (von Frey ΡΠ΅ΡΡ) ΠΈΠ»ΠΈ Π²Π΅ΡΠΈ (ΠΎΡΠΎΡΠ°ΡΠΈΡΠ°Π»Π½ΠΈ Π³Π»ΡΡΠ°ΠΌΠ°ΡΠ½ΠΈ ΡΠ΅ΡΡ) Π°Π½ΡΠΈΠ½ΠΎΡΠΈΡΠ΅ΠΏΡΠΈΠ²Π½ΠΈ Π΅ΡΠ΅ΠΊΠ°Ρ Π²ΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½Π° Ρ ΠΎΠ΄Π½ΠΎΡΡ Π½Π° ΡΡΠΌΠ°ΡΡΠΈΠΏΡΠ°Π½. Π£ ΠΌΠΎΠ΄Π΅Π»Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ½Π΅ ΠΌΠΈΠ³ΡΠ΅Π½Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π½ ΡΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠΊΠΈ Π·Π½Π°ΡΠ°ΡΠ°Π½, ΡΠΏΠΎΡΠ΅Π΄ΠΈΠ² (von Frey ΡΠ΅ΡΡ β Π±Π°Π·Π°Π»Π½Π° ΠΏΡΠ΅ΠΎΡΠ΅ΡΡΠΈΠ²ΠΎΡΡ, ΠΎΡΠΎΡΠ°ΡΠΈΡΠ°Π»Π½ΠΈ Π³Π»ΡΡΠ°ΠΌΠ°ΡΠ½ΠΈ ΡΠ΅ΡΡ ΠΈ ΡΠ΅ΡΡ ΠΊΠΎΠΏΠ°ΡΠ°) ΠΈΠ»ΠΈ Π²Π΅ΡΠΈ (von Frey ΡΠ΅ΡΡ β Π°ΠΊΡΡΠ½Π° ΠΏΡΠ΅ΠΎΡΠ΅ΡΡΠΈΠ²ΠΎΡΡ) Π°Π½ΡΠΈΠ½ΠΎΡΠΈΡΠ΅ΠΏΡΠΈΠ²Π½ΠΈ Π΅ΡΠ΅ΠΊΠ°Ρ Π²ΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½Π° Ρ ΠΎΠ΄Π½ΠΎΡΡ Π½Π° ΠΏΡΠΎΠΏΡΠ°Π½ΠΎΠ»ΠΎΠ».
ΠΠ°ΠΊΡΡΡΠ°ΠΊ: ΠΡΠΈΠΊΠ°Π·Π°Π½ΠΈ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈ ΡΠΊΠ°Π·ΡΡΡ Π΄Π° ΡΠ΅ Π²ΠΎΡΡΠΈΠΎΠΊΡΠ΅ΡΠΈΠ½ ΡΠ΅ Π±Π°ΡΠ΅ΠΌ ΠΏΠΎΡΠ΅Π΄Π±Π΅Π½ΠΎ Π΅ΡΠΈΠΊΠ°ΡΠ°Π½ ΠΊΠ°ΠΎ ΠΈ ΡΠ΅ΡΠ΅ΡΠ΅Π½ΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ Π·Π° ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΌΠΈΠ³ΡΠ΅Π½ΠΎΠ·Π½ΠΈΡ
Π°ΡΠ°ΠΊΠ°/ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΡ ΠΌΠΈΠ³ΡΠ΅Π½Π΅, ΡΡΠΎ ΡΠ΅ Π½Π°Π»Π°Π· ΠΎΠ΄ ΠΌΠΎΠ³ΡΡΠ΅Π³ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΎΠ³ Π·Π½Π°ΡΠ°ΡΠ°.Introduction: Πigraine is recognized as a global health issue, responsible for high population levels of disability and impaired well-being. Above 50% of migraine sufferers are not satisfied with their pain relief strategies. There is evidence of antidepressantsβ efficacy, especially those with multimodal action (amitriptyline), and recommendations for their use in migraine prophylaxis. Vortioxetine is a novel multimodal antidepressant with recently postulated analgesic properties.
The Aim: 1) To examine the efficacy of vortioxetine compared to sumatriptan after acute oral administration in a migraine attack model; and 2) to examine the efficacy of vortioxetine compared to propranolol after repeated prophylactic oral administration in a chronic migraine model.
Material and Methods: The model of a migraine attack was established by acute nitroglycerin injection (10 mg/kg, intraperitoneally), whereas the model of chronic migraine was developed by repeated, intermittent administration of nitroglycerin, every other day, over 9 days in male mice, C57BL/6 strain. Repeated nitroglycerin administration causes chronic basal and acute hypersensitivity. To assess the development of painful hypersensitivity, and the antinociceptive effects of corresponding treatments, stimulus-evoked tests (von Frey test β mechanical stimulus; orofacial glutamate test β chemical stimulus), and non-evoked nociceptive test (burrowing test; also reflecting general animal welfare) were used. The results were analyzed by one-way/two-way ANOVA (Tukey post hoc analysis).
Results: In the migraine attack model, statistically significant, comparable (von Frey test) or higher (orofacial glutamate test) antinociceptive effects of vortioxetine compared to sumatriptan was observed. In the chronic migraine model, vortioxetine showed statistically significant, comparable (von Frey test β basal hypersensitivity, orofacial glutamate and burrowing tests) or higher (von Frey test β acute hypersensitivity) antinociceptive effects compared to propranolol.
Conclusion: The presented results imply that vortioxetine is at least comparably effective as selected referent drugs for migraine attack/migraine prophylaxis treatment, giving clinical importance to our findings